Skip to main content
. 2021 May 10;52(6):2096–2105. doi: 10.1161/STROKEAHA.120.030565

Figure 1.

Figure 1.

Flow chart. ANNEXA-4 indicates Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of FXa Inhibitors; and anti-FXa, anti-factor Xa activity. *Patients not evaluable due to administrative reasons were excluded: n=1 for the spontaneous intracranial hemorrhage (ICrH) population; n=2 for the traumatic ICrH population.